Commentary: Pharma's future is virtual,say Kate Moss and Dr Steve Arlington of PricewaterhouseCoopers
09 July 2008
John Davis
Please Login to read the full article.
09 July 2008
John Davis
In its latest
Pharma 2020: Virtual R&D report on the future of the sector, PricewaterhouseCoopers argues that incremental changes are no longer enough. Companies will need to decide what they want to focus on – whether, for example, to continue playing in a mass market or concentrate...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: With wish granted, Collins forges ahead with new translational science centre
- Experts warn of rapid physician disenchantment as sales forces swell in India
- Broad swathe of measures to support UK life sciences draws widespread applause
- 2012 Scrip 100 Preview: Base jumping for pharma – a slower descent from the patent cliff?
FEATURES
- Merck BioVentures: where biosimilars make a difference
- Chinese producers may be losing price edge to India, says Granules MD
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
